Dysregulation of high-density lipoprotein (HDL) turnover or function may contribute to the excess atherosclerosis in individuals with insulin-resistant (type 2) diabetes and metabolic syndrome. These conditions are characterized by low HDL. However, it is unknown how insulin regulates HDL in normal physiology, or in the pathophysiology of diabetes. FoxO1 is an insulin-repressible transcription factor that has emerged as a key mediator of insulin signaling in liver and the vessel wall. We have determined that FoxO1 regulates multiple genes critical for HDL metabolism and function, and mice lacking hepatic FoxO1 have alterations in HDL lipid and protein content. Thus, we propose that FoxO1 links insulin signaling and HDL.
In Aim 1, we will investigate the hypothesis that FoxO1 regulates selective uptake of HDL-cholesterol in liver. We present preliminary data that FoxO1 regulates multiple steps in this process.
In Aim 2, we will investigate the hypothesis that hepatic FoxO1 regulates macrophage-to-feces reverse cholesterol transport. We will determine the roles of individual HDL genes in the FoxO1 phenotype, and determine the effects on atherosclerosis.
In Aim 3, we will investigate the hypothesis that FoxO1 regulates vasoprotective functions of HDL. We will examine the roles of FoxO1-regulated HDL components in endothelial barrier function and endothelial nitric oxide synthase activity. This work will build on novel hypotheses and a key mouse model to bring insight into the dysregulation of HDL during insulin resistance. The proposed studies will shed light on a key unanswered question in the pathophysiology of atherosclerosis, and reveal new targets for therapeutic intervention.
Diabetes and the metabolic syndrome are major risk factors for cardiovascular disease, which is the leading cause of death in the United States. Impairments in HDL functions such as reverse cholesterol transport or vasoprotection may link these disorders, but the mechanisms remain unclear. Identifying the key players in the relationships between insulin resistance, reverse cholesterol transport, and HDL function will improve our ability to treat patients more effectively.
| Haeusler, Rebecca A; McGraw, Timothy E; Accili, Domenico (2018) Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 19:31-44 |
| Kim, KyeongJin; Goldberg, Ira J; Graham, Mark J et al. (2018) ?-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor. Cell Metab 27:816-827.e4 |
| Higuchi, Sei; Izquierdo, M Concepción; Haeusler, Rebecca A (2018) Unexplained reciprocal regulation of diabetes and lipoproteins. Curr Opin Lipidol 29:186-193 |
| Lee, Samuel X; Heine, Markus; Schlein, Christian et al. (2018) FoxO transcription factors are required for hepatic HDL cholesterol clearance. J Clin Invest 128:1615-1626 |
| Bertaggia, Enrico; Jensen, Kristian K; Castro-Perez, Jose et al. (2017) Cyp8b1 ablation prevents Western diet-induced weight gain and hepatic steatosis because of impaired fat absorption. Am J Physiol Endocrinol Metab 313:E121-E133 |
| Langlet, Fanny; Haeusler, Rebecca A; Lindén, Daniel et al. (2017) Selective Inhibition of FOXO1 Activator/Repressor Balance Modulates Hepatic Glucose Handling. Cell 171:824-835.e18 |
| Haeusler, Rebecca A; Camastra, Stefania; Nannipieri, Monica et al. (2016) Increased Bile Acid Synthesis and Impaired Bile Acid Transport in Human Obesity. J Clin Endocrinol Metab 101:1935-44 |
| Ferrannini, Ele; Camastra, Stefania; Astiarraga, Brenno et al. (2015) Increased Bile Acid Synthesis and Deconjugation After Biliopancreatic Diversion. Diabetes 64:3377-85 |
